NCT07092852
PGx Medication Safety Reviews of Persons With IDD
StatusEnrolling by Invitation
PhaseNot specified
SponsorGalenusRx, Inc.
Primary completion (estimated)
At risk: Primary completion moved 12 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Jul 31, 2027 to Jul 31, 2028 Show 7 more changesShow less
- Enrolling by invitation only
- Start date: Aug 1, 2025 to Dec 1, 2026
- Eligibility criteria expanded, about 5 words
- Study completion pushed from Jan 31, 2028 to Jan 31, 2029
- Study description revised
- Collaborator revised
- Publications: details revised at 3 of 3 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Measure the Feasibility of PGx Testing in IDD Population
Timeframe: Two years
Measure the Acceptability of Implementing a PGx Program
Timeframe: Two years
Secondary (3)
Identify the PGx Profile of CP Unlimited Patients
Identify Drug and Drug Classes of Drug-Gene and Drug-Drug-Gene Interactions
Program Feasibility Considering Data Collection
Arms and interventions
Residents of CP Unlimited
All persons residing in CPU facilities during the study period will be included in the study, except those who are under 21 years of age, in whom a cheek swab cannot be obtained, and those who for whom no valid consent for participation is in place.
Other: Cheek swab for PGx testing, Medication safety review
Sites
2 sites in 1 country